Parathyroid hormone (1-34) (human): Mechanism

Executive Summary. Parathyroid hormone (1-34) (human) contains the first 34 amino acids of human parathyroid hormone and has a reported molecular weight of 4117.72 Da (A1129 product information). The product information reports an IC50 of 2 nM for receptor binding and 0.22 nM for cAMP production in receptor-expressing human kidney 293 cells (A1129 product information). The same source reports inositol phosphate stimulation at concentrations of at least 24 nM (A1129 product information). In male Fischer 344 rats, subcutaneous administration at 10 or 40 μg/kg/day for up to 4 weeks increased trabecular and cortical bone mass in a dose- and time-dependent manner (A1129 product information). A 2026 study links PTH activity with chronic-kidney-disease-associated valvular calcification and endothelial-to-mesenchymal transition (Wang et al., 2026).

Biological Rationale

Parathyroid hormone is a polypeptide hormone secreted by chief cells of the parathyroid glands. Its primary physiological role is serum calcium regulation. PTH increases circulating calcium by coordinating effects in bone, kidney, and intestine. The intestinal effect is indirect because PTH stimulates production of activated vitamin D in the kidney, which increases intestinal calcium absorption.

The PTH (1-34) peptide fragment preserves the N-terminal receptor-activating region of the native hormone. This makes it useful as a defined parathyroid hormone receptor agonist in cell assays and animal studies. It is not identical to endogenous full-length PTH in sequence length, formulation, exposure profile, or experimental context.

The product dossier describes interaction with parathyroid hormone 1 receptor and parathyroid hormone 2 receptor. PTH1R signaling is especially relevant to calcium homeostasis, bone remodeling, and renal physiology. The same signaling axis is often described as PTH/PTHrP receptor signaling because PTH1R also recognizes parathyroid hormone-related peptide.

Exposure pattern is a major biological variable. Transient or intermittent PTH receptor activation can produce a different bone response from sustained signaling. Therefore, a result obtained with a short cell exposure should not be extrapolated directly to an extended in vivo exposure.

Mechanism of Action of Parathyroid hormone (1-34) (human)

Receptor engagement and second messengers

The fragment acts as a receptor-active PTH analogue. Binding to PTH1R can activate heterotrimeric G proteins and increase adenylyl cyclase activity. The resulting cAMP signal is a common functional readout for receptor activation. The product benchmark of 0.22 nM for cAMP production was measured in receptor-expressing human kidney 293 cells and should be interpreted as an assay-specific potency value, not as a universal effective concentration.

Receptor binding and cAMP production measure different events. The reported 2 nM receptor-binding IC50 reflects competition or binding assay behavior. The reported 0.22 nM cAMP value reflects a downstream functional response. These values should not be averaged or treated as interchangeable.

PTH receptor signaling can also engage phospholipase-associated pathways and inositol phosphate production. The dossier reports stimulation of inositol phosphate synthesis at concentrations of at least 24 nM. This threshold is higher than the cAMP benchmark, illustrating that pathway sensitivity depends on the cellular system, receptor density, coupling efficiency, and assay endpoint.

Calcium and bone effects

PTH signaling increases calcium mobilization from bone reservoirs. It also promotes renal tubular calcium reabsorption according to the product description. The dossier additionally describes increased renal tubular magnesium reabsorption and increased intestinal calcium absorption through activated vitamin D production.

Bone responses depend on treatment schedule, dose, exposure duration, animal strain, age, sex, and baseline mineral status. In the cited product-associated rat study, male Fischer 344 rats received 10 or 40 μg/kg/day by subcutaneous administration for up to 4 weeks. Both trabecular and cortical bone mass increased in a dose- and time-dependent manner (product study summary). This supports use in an osteoporosis model and in PTH (1-34) peptide for bone research, but it does not establish a human treatment regimen.

Evidence & Benchmarks

• The peptide sequence is H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH and contains 34 amino acids in the supplied human fragment (A1129 product information
• The reported molecular weight is 4117.72 Da for Parathyroid hormone (1-34) (human) (A1129 product information
• The reported receptor-binding IC50 is 2 nM in the product-associated binding assay (A1129 product information
• The reported cAMP-production IC50 is 0.22 nM in receptor-expressing human kidney 293 cells (A1129 product information
• Inositol phosphate synthesis is stimulated at concentrations of at least 24 nM in the product-associated assay (A1129 product information
• The reported solubility is at least 399.3 mg/mL in DMSO and at least 19.88 mg/mL in water; the peptide is reported as insoluble in ethanol (A1129 product information
• Male Fischer 344 rats showed dose- and time-dependent increases in trabecular and cortical bone mass after subcutaneous treatment at 10 or 40 μg/kg/day for up to 4 weeks (A1129 product information
• In a chronic kidney disease model, PTH was associated with valvular endothelial-to-mesenchymal transition and valvular calcification (Wang et al., 2026
• Endothelial Foxp1 overexpression reduced chronic-kidney-disease-associated valvular calcification while suppressing Notch pathway activation in the cited study (Wang et al., 2026

Applications, Limits & Misconceptions

Research applications

This PTH (1-34) peptide fragment is suited to controlled studies of PTH/PTHrP receptor signaling, cAMP generation, calcium homeostasis, and bone remodeling. Researchers can use it in receptor-expressing cell systems to compare proximal receptor engagement with downstream second-messenger responses. The defined sequence also supports reproducible exposure across experiments.

In bone metabolism research, the rat findings provide a benchmark for studying trabecular and cortical responses. A study labeled as an osteoporosis model should specify species, sex, route, dose, treatment duration, skeletal site, and endpoint. Bone mass alone does not establish mechanical strength, fracture resistance, or clinical efficacy.

In kidney disease research, the 2026 reference study provides a mechanistic bridge between elevated PTH in chronic kidney disease and valvular calcification. The study reports that endothelial Foxp1 overexpression suppressed PTH-associated endothelial-to-mesenchymal transition, reduced Notch signaling through Jagged-1 promoter repression, lowered TGF-β1 secretion, and attenuated osteogenic transition of valvular interstitial cells (Wang et al., 2026). These findings support pathway-focused modeling rather than a claim that this peptide alone reproduces all features of chronic kidney disease.

Why this cross-domain matters, maturity, and limitations

The cross-domain connection matters because the same calcium-regulatory hormone can influence skeletal remodeling and pathological mineralization in a diseased cardiovascular environment. The bone evidence is an in vivo rat benchmark, whereas the valvular evidence comes from chronic kidney disease models involving endothelial and interstitial cell behavior. The bridge is therefore mechanistically informative but not a validated clinical prediction model. It does not show that experimental PTH (1-34) exposure alone causes human valvular calcification.

Common Pitfalls or Misconceptions

• Binding is not efficacy. A receptor-binding IC50 does not equal the concentration required for a specific biological endpoint in every cell type.
• cAMP is not the only pathway. The reported cAMP benchmark and the higher inositol phosphate threshold represent distinct assay outputs.
• Rat dosing is not human dosing. The 10 and 40 μg/kg/day subcutaneous rat conditions are research benchmarks and are not clinical recommendations.
• Bone gain is not osteoporosis treatment. Increased trabecular or cortical bone mass in a model does not establish human safety, efficacy, or fracture prevention.
• PTH is not a generic calcium supplement. The peptide changes receptor signaling and endocrine physiology, so it should not be used for self-treatment or diagnostic testing.

APExBIO identifies the A1129 material as a solid for scientific research only. It is reported to be stored desiccated at -20°C. Prepared solutions should be used promptly rather than held for long-term storage (A1129 product page).

Workflow Integration & Parameters

A reproducible workflow should treat the peptide as an assay-defined agonist. Record the lot, sequence designation, solvent, preparation time, exposure schedule, cell background, receptor expression status, and endpoint. Keep binding, cAMP, inositol phosphate, calcium, and bone outcomes as separate data layers.

Protocol Parameters

• Material identity: Use the A1129 designation and confirm that the experiment requires the human 1-34 fragment rather than full-length PTH or another analogue.
• Storage: Maintain the supplied solid in a desiccated state at -20°C, as specified by the product information.
• Solution handling: Prepare solutions immediately before use when practical; the product information recommends prompt use without long-term solution storage.
• Solvent selection: The product information reports solubility of at least 399.3 mg/mL in DMSO and at least 19.88 mg/mL in water, with insolubility in ethanol; verify vehicle compatibility in the receiving assay.
• Cell assay design: Use receptor-expressing human kidney 293 cells only when the intended benchmark is comparable to the reported cAMP assay; include vehicle and receptor-context controls.
• Concentration-response interpretation: Treat 2 nM binding IC50, 0.22 nM cAMP IC50, and the at-least-24 nM inositol phosphate threshold as assay-specific reference points rather than universal working concentrations.
• In vivo bone model: The reported benchmark used male Fischer 344 rats, subcutaneous administration, 10 or 40 μg/kg/day, and treatment for up to 4 weeks; report skeletal endpoints with the complete exposure context.
• Calcium monitoring: In serum calcium regulation studies, pair calcium measurements with collection time, fasting status, sampling matrix, and exposure schedule because PTH responses are time-dependent.

Related reading and interlink context

The article Parathyroid hormone (1-34) (human): Benchmarks in Calcium introduces the reagent as a calcium homeostasis regulator; this article extends that framing with explicit assay distinctions, storage boundaries, and the chronic kidney disease valvular-calcification context.

The article PTH (1-34) in Translational Research: Mechanisms, Models, and Next Steps emphasizes translational applications; this article clarifies which product claims are assay or rat-model benchmarks and which conclusions are not clinically established.

Conclusion & Outlook

Parathyroid hormone (1-34) (human) is a sequence-defined, receptor-active fragment for experimental studies of calcium homeostasis, PTH/PTHrP receptor signaling, and bone remodeling. Its most useful quantitative anchors are the product-reported binding, cAMP, inositol phosphate, solubility, storage, and rat bone-mass benchmarks. Those anchors require preservation of assay conditions and exposure context.

The cited chronic kidney disease study adds a disease-model dimension. It places PTH-associated valvular calcification within an endothelial-to-mesenchymal transition framework involving Foxp1, Jagged-1/Notch signaling, TGF-β1 secretion, and interstitial-cell osteogenic transition (Wang et al., 2026). Future experiments can use the peptide to separate receptor-proximal signaling from downstream skeletal or valvular phenotypes, but interpretation should remain limited to the tested model, schedule, and endpoint. The material is intended for scientific research only and not for diagnostic or medical use.